B群链球菌表面蛋白FbsA的提取及免疫原性初步探讨

发布时间：2018-03-31 10:26

  本文选题：B群链球菌　切入点：FbsA　出处：《北京生物制品研究所》2008年硕士论文

【摘要】： B群链球菌(GBS)是新生儿感染的重要原因,可引起新生儿肺炎.败血症和脑膜炎,同时也可引起免疫功能低下的成年人的蜂窝组织炎、关节炎、心内膜炎及尿路感染等。GBS疫苗的发展主要经历了荚膜多糖疫苗、荚膜多糖—蛋白结合疫苗两个阶段,现在正在研究蛋白疫苗。目前,GBS的许多表面蛋白被相继发现,蛋白疫苗、多价蛋白疫苗有望成为控制GBS感染的疫苗。FbsA是能够与人纤维蛋白原结合的GBS表面蛋白,被认为是GBS的重要侵袭因子,与GBS侵入粘膜上皮细胞、血小板凝集、抗吞噬细胞的吞噬及免疫逃逸等有关。所以FbsA有可能成为有效阻止GBS感染的蛋白疫苗。本实验通过获取GBSⅢ型32325株表面蛋白,再通过等电沉淀法,聚丙烯酸沉淀法和凝胶过滤纯化获得GBS表面蛋白FbsA。并通过合成FbsA的重复16肽GNVLERRQRDAENRSQ再与牛血清白蛋白偶联所形成的抗原免疫家兔获得抗血清鉴定所纯化的抗原。将纯化的FbsA以不同剂量和针次免疫NIH小鼠,用间接ELISA法检测小鼠血清抗体的滴度。结果表明,5μg免疫3次可获得较高的抗体滴度且有免疫记忆。在此基础上,初步探讨了抗FbsA血清的中和作用。
[Abstract]:Group B streptococcus is an important cause of neonatal infection, causing neonatal pneumonia, septicemia and meningitis, as well as cellulitis and arthritis in adults with low immune function. The development of GBS vaccine, such as endocarditis and urinary tract infection, mainly went through two stages of capsule polysaccharide vaccine and capsule polysaccharide protein-binding vaccine. Now protein vaccine is being studied. At present, many surface proteins of GBS have been discovered one after another, protein vaccine. Multivalent protein vaccine is expected to be a vaccine to control GBS infection. FbsA is a surface protein of GBS that can bind to human fibrinogen. It is considered to be an important invading factor of GBS. It is associated with GBS invasion of mucosal epithelial cells and platelet agglutination. Therefore, FbsA may be an effective protein vaccine to prevent GBS infection. In this study, the surface proteins of 32325 strains of GBS type 鈪，

本文编号：1690330